Effect of Folic Acid in Levodopa Treated Parkinson's Disease Patients
Parkinson Disease
About this trial
This is an interventional treatment trial for Parkinson Disease
Eligibility Criteria
Inclusion Criteria: Diagnosed PD patients taking levodopa for at least 6months. Mild to moderate Parkinson's disease patient according to Hoehn and Yahr staging, stage -I, II, III Homocysteine level ≥ 13 µmol/L Exclusion Criteria: Secondary causes of parkinsonism Prior stereotactic surgery for PD Suffering from active malignancy Known hypersensitivity to folic acid Multivitamin supplementation within 30 days of enrollment Patients taking anticonvulsant, oral contraceptive pill, disease modifying anti-rheumatic drugs Pregnancy or lactating mother Has any clinically significant medical condition that could interfere with the subject's ability to safely participate in the study or to be followed
Sites / Locations
- BSMMURecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Folic acid
Control
30 patinets will receive Orally 5mg tablet two times daily for 8 weeks
30 patinets will receive Orally 5mg tablet two times daily for 8 weeks